iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy...

iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual
Colonoscopy CAD Product

NASHUA, N.H., Jan. 22 /PRNewswire-FirstCall/ -- iCAD, Inc. (Nasdaq: ICAD),
an industry-leading provider of Computer-Aided Detection (CAD) solutions for
the early identification of cancer, today announced an agreement with ACR
Image Metrix to conduct a multi-reader clinical study of iCAD's CT Colon
product, for use with Virtual Colonoscopy. With this partnership, iCAD will
work with ACR Image Metrix to develop and execute a clinical study to support
U.S. Food and Drug Administration (FDA) approval of CT Colon CAD. ACR Image
Metrix was launched by the American College of Radiology (ACR) to leverage
over thirty years of experience in conducting clinical research in part
through the American College of Radiology Imaging Network (ACRIN). The ACR and
the ACRIN have a proven history in developing trials that standardize the use
of imaging technologies, image transmission and archive, reduce the size and
cost of trials and produce more reliable results.
"This partnership represents a major step forward in the development of
our Colon CAD product," said Ken Ferry, President and Chief Executive Officer
of iCAD. "We feel that working with ACR Image Metrix, a group with
significant expertise in radiology clinical trial management, will put us in
an optimal position to submit solid clinical data to FDA and meet our goals
for this important product line."
Although 140,000 people in the U.S. will be diagnosed with colon cancer
this year, the good news is it is one of the most treatable cancers when
detected early. More than 82 million Americans are over 50 and are eligible
for colorectal cancer screening, however the test is significantly
underutilized, due at least in part to the invasive nature of current
screening procedures. Results from recent trials showing the effectiveness of
Virtual Colonoscopy as a screening procedure coupled with recent legislation
introduced to establish Medicare reimbursement for the procedure are likely to
expand the options available for colorectal cancer screening and increase
utilization of Virtual Colonoscopy.
"It is clear from the low compliance levels that we need more options in
colon cancer screening," said Bruce J. Hillman, M.D., F.A.C.R., ACR Image
Metrix Director of Scientific Affairs. "We feel that CT Colonography has the
potential to drastically improve colon cancer screening and we look forward to
exploring how CAD can impact and enhance this new option for detecting
polyps." Dr. Hillman was the Chair of ACRIN and played a pivotal role in
advancing several national trials including the National CT Colonography Trial
that recently demonstrated that CTC is highly accurate for the detection of
intermediate and large polyps and that the accuracy of CTC is similar to
colonoscopy.
About ACR Image Metrix
ACR Image Metrix is a subsidiary of the American College of Radiology
(ACR), the premier professional society serving more than 32,000 radiologists
committed to ensuring that imaging is safe, effective, and accessible to all
patients. ACR Image Metrix is based on the successes of ACRIN(R), the NCI-
funded clinical trials cooperative group established in 1999 to assess
emerging imaging technologies. ACRIN(R)'s clinical trials have involved as few
as 65 to more than 50,000 subjects and have handled over 50 million images.
The ACRIN(R) portfolio includes such high-profile studies as the Digital
Mammographic Imaging Screening Trial (DMIST) and the National Lung Cancer
Screening Trial (NLST).
About iCAD, Inc.
iCAD, Inc. (Nasdaq: ICAD) is an industry-leading provider of Computer-
Aided Detection (CAD) solutions that enable healthcare professionals to better
serve patients by identifying pathologies and pinpointing cancer earlier. iCAD
offers a comprehensive range of high-performance, upgradeable CAD systems for
the high, mid and low volume mammography markets. iCAD is entrusted with the
task of early cancer detection by over 1500 women's healthcare centers
worldwide. For more information, call +1 877 iCADnow or visit
www.icadmed.com.For iCAD, contact Darlene Deptula-Hicks, EVP and CFO at
603-882-5200 x7944 or
via email at ddeptula@icadmed.com
For iCAD Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn &
Associates at 212-838-3777 x6604 or via email at icad@lhai.com
For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at
781-684-0770 or via email at icad@schwartz-pr.com
"Safe Harbor" Statement under the Private Securities Litigation Reform Act
of 1995:
Certain statements contained in this News Release constitute "forward-
looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve a number of known
and unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the Company to be materially different
from any future results, performance or achievements expressed or implied by
such forward-looking statements. Such factors include, but are not limited to,
the risks of uncertainty of patent protection, the impact of supply and
manufacturing constraints or difficulties, product market acceptance, possible
technological obsolescence, increased competition, customer concentration and
other risks detailed in the Company's filings with the Securities and Exchange
Commission. The words "believe", "demonstrate", "intend", "expect",
"estimate", "anticipate", "likely", and similar expressions identify forward-
looking statements. Readers are cautioned not to place undue reliance on those
forward-looking statements, which speak only as of the date the statement was
made. The Company is under no obligation to provide any updates to any
information contained in this release.
SOURCE iCAD, Inc.

Darlene Deptula-Hicks, EVP and CFO of iCAD, Inc., +1-603-882-5200, Ext. 7944,
ddeptula@icadmed.com; Investor Relations, Anne Marie Fields of
Lippert-Heilshorn & Associates, +1-212-838-3777, Ext. 6604, icad@lhai.com, for
iCAD, Inc.; or Public Relations, Wendy Ryan of Schwartz Communications,
+1-781-684-0770, icad@schwartz-pr.com, for iCAD, Inc.